How do you manage patients with refractory OAB?

Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

"In terms of making it a safe, highly reliable operation, if you're comfortable with slings and sphincters, you are very well positioned to learn this surger," says Kiran Sury, MD.

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

The 52-week study plans to enroll 16 patients across 4 sites in the US.

The ARID II trial is assessing the safety and effectiveness of the device in men who are scheduled to undergo robotic-assisted radical prostatectomy.